Conference Coverage
News
Move from awareness to action to combat racism in medicine
Calls to action to address structural racism include learning from policies, prioritizing voting, and educating children.
Conference Coverage
Hep B vaccine response varied among youth with inflammatory, autoimmune disorders
While the vaccine series provides protection in healthy individuals more than 95% of the time, a decreased response has been noted in specific...
News
Febrile infant guideline allows wiggle room on hospital admission, testing
Evidence-based guidelines use language to guide, but not direct, clinicians in balancing the risks of infections and invasive procedures.
Conference Coverage
Physicians question the future of TNF inhibitors for psoriasis, PsA
Two dermatologists and two rheumatologists debate the merits of using IL-17 and IL-23 inhibitors ahead of TNF inhibitors for the treatment of...
Conference Coverage
COVID-19 tied to acceleration of Alzheimer’s disease pathology
Patients with Alzheimer’s disease are at threefold higher risk for COVID infection and have a twofold higher risk for death.
Conference Coverage
‘Alarming’ data on early cognitive decline in transgender adults
“Trans populations are disproportionately impacted by health disparities and also risk factors for dementia.”
Conference Coverage
Low-dose aspirin linked to lower dementia risk in some
Two cohorts suggest long-term use may be beneficial, but primarily in those with cardiovascular risk.
Conference Coverage
Short sleep is linked to future dementia
Decades of follow-up suggest sleep disruption is a true risk factor, not a warning sign.
Conference Coverage
ESC heart failure guideline to integrate bounty of new meds
It has a simple answer to a seemingly complex issue: how to merge the newly approved with mainstay drug therapies. And it conditionally okays meds...
Conference Coverage
‘Staggering’ increase in global dementia cases predicted by 2050
Estimates of expected increases can and should inform policy and planning efforts, researchers say.
Conference Coverage
First guidance on appropriate use of controversial Alzheimer’s drug
“This is a first-in-class drug where the vast majority of clinicians have no experience with it.”